Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 10
Submit an article Journal homepage
193
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Allogeneic stem cell transplantation and combination antiretroviral therapy: cautions, complications, and considerations

Rory M. ShallisDivision of Hematology, Department of Medicine, Yale University School of Medicine, New Haven, CT, USA; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-8542-2944
ORCID Icon,
Shana GleesonDepartment of Internal Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, CT, USA;
,
Marwan M. AzarDepartment of Internal Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, CT, USA;
,
Maricar MalinisDepartment of Internal Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, CT, USA;
,
Mina L. XuDepartment of Pathology, Yale University, New Haven, CT, USA;
,
Stuart E. SeropianDivision of Hematology, Department of Medicine, Yale University School of Medicine, New Haven, CT, USA;
,
Lohith GowdaDivision of Hematology, Department of Medicine, Yale University School of Medicine, New Haven, CT, USA;
&
Amer M. ZeidanDivision of Hematology, Department of Medicine, Yale University School of Medicine, New Haven, CT, USA; ;Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA
 show all
Pages 2584-2587 | Received 09 Jan 2019, Accepted 06 Mar 2019, Published online: 03 Apr 2019

References

  • Ambinder RF, Wu J, Logan B, et al. Allogeneic hematopoietic cell transplant (alloHCT) for hematologic malignancies in human immunodeficiency virus infected (HIV) patients (pts): Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0903)/AIDS Malignancy Consortium (AMC-080) trial. Jco. 2017;35:7006.
  • Alvarnas JC, Zaia JA, Forman SJ. How I treat patients with HIV-related hematological malignancies using hematopoietic cell transplantation. Blood. 2017;130:1976–1984.
  • Hutter G, Zaia JA. Allogeneic haematopoietic stem cell transplantation in patients with human immunodeficiency virus: the experiences of more than 25 years. Clin Exp Immunol. 2011;163:284–295.
  • Llibre JM, Young B. Unplanned antiretroviral treatment interruptions, genetic barrier, and development of resistance. HIV Med. 2014;15:193–195.
  • Kalmar EM, Sanabani SS, Charlys da Costa A, et al. Evaluation of HIV-1 resistance to antiretroviral drugs among 150 patients after six months of therapeutic interruption. Int J STD Aids. 2012;23:120–125.
  • Antoniou T, Tseng AL. Interactions between antiretrovirals and antineoplastic drug therapy. Clin Pharmacokinet. 2005;44:111–145.
  • Poonkuzhali B, Chandy M, Srivastava A, et al. Glutathione S-transferase activity influences busulfan pharmacokinetics in patients with beta thalassemia major undergoing bone marrow transplantation. Drug Metab Dispos. 2001;29:264–267.
  • Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet. 2002;41:93–103.
  • Johnston C, Harrington R, Jain R, et al. Safety and efficacy of combination antiretroviral therapy in human immunodeficiency virus-infected adults undergoing autologous or allogeneic hematopoietic cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2016;22:149–156.
  • Brown KC, Paul S, Kashuba AD. Drug interactions with new and investigational antiretrovirals. Clin Pharmacokinet. 2009;48:211–241.
  • Yamazaki T, Desai A, Han D, et al. Pharmacokinetic interaction between isavuconazole and a fixed-dose combination of lopinavir 400 mg/ritonavir 100 mg in healthy subjects. Clin Pharmacol Drug Dev. 2017;6:93–101.
  • Mulanovich VE, Desai PA, Popat UR. Allogeneic stem cell transplantation for HIV-positive patients with hematologic malignancies. AIDS. 2016;30:2653–2657.
  • Henrich TJ, Hu Z, Li JZ, et al. Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis. 2013;207:1694–1702.
  • Mills A, Arribas JR, Andrade-Villanueva J, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis. 2016;16:43–52.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.